Domů › Rakovina plic › Kalifornie › San Francisco
Klinické studie Rakovina plic v San Francisco, CA
22 studií pro Rakovina plic hledá účastníky v lokalitách v San Francisco a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Study of ZW251 in Participants With Advanced Solid Tumors
Probíhá náborFáze 1
- UCSF Comprehensive Cancer Center, San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Probíhá náborFáze 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Probíhá náborFáze 3
- Kaiser Permanente-San Francisco, San Francisco
Smoking Cessation CM for Veterans With or at Risk for Cancer
Probíhá náborVítáni zdraví dobrovolníci
- San Francisco VA Medical Center, San Francisco, CA, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Probíhá nábor
- Kaiser Permanente-San Francisco, San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Probíhá náborFáze 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Probíhá náborFáze 3
- San Francisco Oncology Associates ( Site 0066), San Francisco
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Probíhá náborFáze 1/2
- University of California, San Francisco (UCSF), San Francisco
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Probíhá náborFáze 3
- California Pacific Medical Center, San Francisco
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Probíhá náborFáze 1
- University of California San Francisco, San Francisco
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Probíhá náborFáze 3
- UCSF Medical Center-Mission Bay, San Francisco
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Probíhá náborFáze 3
- California Pacific Medical Center-Pacific Campus, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Probíhá náborFáze 2
- University of California San Francisco, San Francisco
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Probíhá náborFáze 1/2
- UCSF Medical Center - Mission Bay, San Francisco
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Probíhá náborFáze 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Probíhá náborFáze 2/3
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Probíhá náborFáze 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Probíhá nábor
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Probíhá náborFáze 1/2
- University of California at San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Probíhá náborFáze 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Probíhá náborFáze 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, San Francisco
Studie Rakovina plic v jiných městech
- Houston, TX78 studií
- Boston, MA62 studií
- New York City, NY60 studií
- Los Angeles, CA45 studií
- Arlington, VA41 studií
- Washington, DC41 studií
- Chicago, IL41 studií
- Baltimore, MD40 studií
- Nashville, TN40 studií
- St. Louis, MO39 studií
- Columbus, OH37 studií
- Philadelphia, PA36 studií
Další studie v San Francisco
- Rakovina prostaty45 studií
- Rakovina prsu43 studií
- Nemalobuněčný plicní karcinom36 studií
- Rakovina (všechny typy)35 studií
- Srdeční selhání29 studií
- Metastatický karcinom28 studií
- Melanom22 studií
- Rakovina slinivky břišní20 studií
- Rakovina vaječníků19 studií
- Kolorektální karcinom18 studií
- Kardiovaskulární onemocnění18 studií
- Glioblastom17 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.